https://www.nasdaq.com/press-release/alterity-therapeutics-to-present-at-the-h.c.-wainwright-bioconnect-virtual-conference
https://www.nasdaq.com/press-release/alterity-therapeutics-announces-first-regulatory-authorization-to-proceed-with-ath434
https://www.nasdaq.com/press-release/alterity-therapeutics-to-participate-in-two-upcoming-investor-conferences-2021-11-22
https://www.nasdaq.com/press-release/alterity-therapeutics-announces-presentation-of-ath434-at-the-american-autonomic
https://www.nasdaq.com/press-release/alterity-therapeutics-announces-new-publications-providing-further-evidence-of-the-0
https://www.nasdaq.com/press-release/alterity-therapeutics-announces-new-publications-providing-further-evidence-of-the
https://www.nasdaq.com/press-release/appendix-4c-q1-fy22-quarterly-cash-flow-report-2021-10-29
https://www.nasdaq.com/press-release/alterity-therapeutics-announces-expanded-ath434-phase-2-clinical-development-program
https://www.nasdaq.com/press-release/alterity-announces-presentation-of-biomarker-data-at-the-international-parkinson-and
https://www.nasdaq.com/press-release/alterity-therapeutics-announces-new-us-patent-to-expand-its-portfolio-of-compounds
https://www.nasdaq.com/press-release/appendix-4c-q4-fy21-quarterly-cash-flow-report-2021-07-30
https://www.nasdaq.com/press-release/alterity-therapeutics-announces-publication-of-data-demonstrating-ath434-is
https://www.nasdaq.com/press-release/alterity-therapeutics-granted-a-new-us-patent-targeting-major-neurodegenerative
https://www.nasdaq.com/press-release/alterity-therapeutics-limited-received-european-union-regulatory-guidance-for-ath434
https://www.nasdaq.com/press-release/alterity-therapeutics-limited-appendix-4c-q3-fy21-quarterly-cash-flow-report-2021-04
https://www.nasdaq.com/press-release/ath434-protects-brain-cells-and-improves-motor-function-in-parkinsonian-disorder-2021
https://www.nasdaq.com/press-release/alterity-to-present-at-the-7th-international-congress-of-multiple-system-atrophy-2021
https://www.nasdaq.com/press-release/alterity-therapeutics-announces-funding-from-michael-j.-fox-foundation-for-ath434
https://www.nasdaq.com/press-release/dr-david-stamler-appointed-ceo-2021-01-07
https://www.nasdaq.com/press-release/alterity-and-uniquest-partner-to-reverse-bacterial-resistance-to-antibiotics-2020-12
